Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging
- PMID: 26488875
- DOI: 10.1159/000439097
Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging
Abstract
Background: The diagnosis of intrahepatic cholangiocellular carcinoma (ICC) remains elusive at imaging, which is a critical issue in cirrhotic patients in whom a diagnosis of hepatocellular carcinoma (HCC) can be established only by imaging.
Aim: The aim of the study was to evaluate the potential of MRI in the diagnosis of ICC in cirrhosis using 'hepatocyte-specific' Gadolinium (Gd)-based contrast agents.
Methods: Sixteen histologically proven and retrospectively identified ICCs on cirrhosis were investigated with hepatocyte-specific magnetic resonance contrast agents (6 in Bologna with Gd-EOB-DTPA and 10 in Milan with Gd-BOPTA). The control group consisted of 41 consecutively and prospectively collected nodules (31 HCCs) imaged with Gd-EOB-DTPA.
Results: Fifteen ICC nodules (94%) displayed hypointensity in the hepatobiliary phase, suggesting malignancy. Thirteen cholangiocarcinomas (81%) showed hyperenhancement in the venous phase. Only 2 cholangiocarcinoma nodules showed hypoenhancement in the venous phase, corresponding to washout, in both cases preceded by rim enhancement in arterial phase. All the hepatocarcinomas showed hypointensity in hepatobiliary phase, but was always preceded by hypointensity in the venous phase; arterial rim enhancement was never observed in any hepatocarcinoma or regenerative nodule.
Conclusions: MRI with hepatocyte-specific Gd-based contrast agents showed a pattern of malignancy in almost all the ICCs, concurrently avoiding misdiagnosis with hepatocarcinoma. These findings suggest a greater diagnostic capacity for this technique compared with the results of MRI with conventional contrast agents reported in the literature in this setting.
© 2015 S. Karger AG, Basel.
Similar articles
-
Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.Hepatology. 2009 Sep;50(3):791-8. doi: 10.1002/hep.23071. Hepatology. 2009. PMID: 19610049
-
Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.J Magn Reson Imaging. 2013 Apr;37(4):892-902. doi: 10.1002/jmri.23873. Epub 2012 Oct 23. J Magn Reson Imaging. 2013. PMID: 23097278
-
Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study.Aliment Pharmacol Ther. 2013 Feb;37(3):355-63. doi: 10.1111/apt.12166. Epub 2012 Dec 2. Aliment Pharmacol Ther. 2013. PMID: 23199022
-
Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines.Dig Dis. 2014;32(6):696-704. doi: 10.1159/000368002. Epub 2014 Oct 29. Dig Dis. 2014. PMID: 25376286 Review.
-
Primovist, Eovist: what to expect?J Hepatol. 2012 Aug;57(2):421-9. doi: 10.1016/j.jhep.2012.01.031. Epub 2012 Apr 12. J Hepatol. 2012. PMID: 22504332 Review.
Cited by
-
Preoperative differentiation of hepatocellular carcinoma with peripheral rim-like enhancement from intrahepatic mass-forming cholangiocarcinoma on contrast-enhanced MRI.Front Oncol. 2022 Nov 23;12:986713. doi: 10.3389/fonc.2022.986713. eCollection 2022. Front Oncol. 2022. PMID: 36505850 Free PMC article.
-
Diagnostic performance of magnetic resonance imaging and contrast-enhanced ultrasound in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma: a meta-analysis.Abdom Radiol (NY). 2024 Jan;49(1):34-48. doi: 10.1007/s00261-023-04064-z. Epub 2023 Oct 12. Abdom Radiol (NY). 2024. PMID: 37823913
-
Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5).Cancers (Basel). 2022 Jan 11;14(2):336. doi: 10.3390/cancers14020336. Cancers (Basel). 2022. PMID: 35053498 Free PMC article.
-
Hereditary breast cancer: screening and risk reducing surgery.Gland Surg. 2019 Sep;8(Suppl 3):S142-S149. doi: 10.21037/gs.2019.04.04. Gland Surg. 2019. PMID: 31559181 Free PMC article.
-
Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma.Cancer Imaging. 2019 Dec 5;19(1):84. doi: 10.1186/s40644-019-0266-9. Cancer Imaging. 2019. PMID: 31806050 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical